Clinical impact of PET/MR in treated colorectal cancer patients
Bárbara Juarez Amorim(Harvard University), Onofrio A. Catalano(Harvard University), Rocco Ricciardi(Massachusetts General Hospital), Márk Vangel(Massachusetts General Hospital), David Groshar(Tel Aviv University), Theodore S. Hong(Massachusetts General Hospital), Liliana Bordeianou(Massachusetts General Hospital), David L. Berger(Harvard University), Lale Umutlu(Essen University Hospital), Cristina R. Ferrone(Cedars-Sinai Medical Center), Umar Mahmood(Athinoula A. Martinos Center for Biomedical Imaging), Lina Garcia Cañamaques(Hospital Universitario HM Sanchinarro), David P. Ryan(East Carolina University), Jennifer Y. Wo(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Bruce R. Rosen(Massachusetts General Hospital), Debra A. Gervais(Massachusetts General Hospital), Motaz Qadan(Massachusetts General Hospital)
Cited by 32
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes
|Nature Biotechnology|1999|1.6k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k